Loading patent…
AssigneesServices, The Government of the US as Represented by the Secretary of the Department of Health and Human
InventorsRalph A. Tripp, Les Jones, Larry J. Anderson
Estimating the term…
Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
A composition comprising a blocking molecule that inhibits the biological activity of a CX3C motif of a respiratory syncytial virus G glycoprotein, wherein C is a cysteine residue and X is any amino acid residue other than cysteine.
(canceled)
(canceled)
A respiratory syncytial virus comprising a CX3C motif of the respiratory syncytial G glycoprotein which is nonfunctional for attachment to CX3CR1 on cells, wherein C is a cysteine residue and X is any amino acid residue other than cysteine.
A method for identifying a substance useful for the treatment or prevention of respiratory syncytial virus disease comprising contacting the substance with a CX3C receptor, in the presence of respiratory syncytial virus G glycoprotein, and detecting inhibition of glycoprotein binding to the CX3C receptor, whereby detection of inhibition of respiratory syncytial virus G glycoprotein binding to the CX3C receptor identifies a substance useful for the treatment or prevention of respiratory syncytial virus disease.
A method for identifying a substance for the treatment or prevention of respiratory syncytial virus disease comprising contacting the substance with a CX3C receptor containing cell, in the presence of respiratory syncytial virus, and detecting inhibition of a biological activity associated with respiratory syncytial virus binding to the CX3C receptor, whereby detection of inhibition of a biological activity associated with respiratory syncytial virus binding to the CX3C receptor identifies a substance useful for the treatment or prevention of respiratory syncytial virus disease.
(canceled)
(canceled)
Dependencies are inferred from the claim text.